Junnan Xu, Mingxi Jing, Zhichao Gao, Tao Sun

Department of Internal Oncology, Shenyang LiaoningCancer Hospital & Institute

Objective:Bone metastases from breast cancer causedmore skeletal-related events and worse clinical survival. Developing breastcancer may be contribute to alter serum lipid profile. However, role of serumlipid profile in bone metastases in patients with breast cancer is stillunclear. The major aim of this study is to examine the role of serum lipid profilein developing bone metastasis from breast cancer. Method: Serum lipidsincluding total cholesterol (TC), high-density lipoprotein (HDL), low-densitylipoprotein (LDL), and triglycerides (TG) were analyzed from 737 control patientswithout bone metastases and 289 breast cancer patients developing bone metastases.The Kaplan-Meier method was used to calculate the cumulative survival rate. Coxproportional hazard regression models were used to analyze the risk of bonemetastases from breast cancer associated with serum lipid profile adjusting forclinicopathologic variables. Result: Data of 1,026 patients who werediagnosed with breast cancer during 2001-2014 were collected and used foranalysis. The median follow-up duration was 3.67 years. In the multivariateanalysis, HDL was associated with 28.8% decreased bone metastases risk (OR,0.712; 95% CI, 0.548-0.924, P<0.05) and was an independentlysignificant risk factor for bone metastases from breast cancer. However, TC(OR, 1.007; 95% CI, 0.760-1.335), LDL (OR, 1.184; 95% CI, 0.844-1.661), and TG(OR, 0.855; 95% CI, 0.647-1.129) were not significantly associated with bonemetastases from breast cancer. Bone metastases event developed in 170 cases(25.1%) in normal HDL group and bone metastases event developed in 119 cases(34.3%) in low HDL group (P<0.01). Conclusion: These datasuggests for the first time that an lower HDL-C may be a risk factor for bonemetastasis from breast cancer.

Key Words: bone metastases  breast cancer high density lipoprotein